2-羟基-3-喹啉羧酸 | 2003-79-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-羟基-3-喹啉羧酸
• 中文别名: 2-羰基-1,2-二氢3-喹啉甲酸
• 英文名称: 2-oxo-1,2-dihydro-quinoline-3-carboxylic acid
• 英文别名: quinolin-2(1H)-one-3-carboxylic acid；2-oxo-1H-quinoline-3-carboxylic acid
• CAS: 2003-79-4
• 化学式: C₁₀H₇NO₃
• mdl: MFCD01550054
• 分子量: 189.17
• InChiKey: XOQQVKDBGLYPGH-UHFFFAOYSA-N

物化性质

• 熔点：
  330-332°C
• 沸点：
  440.9±45.0 °C(Predicted)
• 密度：
  1.429±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933790090
• 危险性防范说明：
  P280,P302+P352,P261,P312,P304+P340,P280,P305+P351+P338
• 危险性描述：
  H335,H302,H312,H315,H332,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Oxo-1,2-dihydro-quinoline-3-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Oxo-1,2-dihydro-quinoline-3-carboxylic acid
CAS number: 2003-79-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H7NO3
Molecular weight: 189.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-羟基-3-喹啉羧酸 在 氯化亚砜 作用下， 反应 1.5h， 生成 2-氯-3-喹啉羰酰氯
  参考文献：
  名称：

  一些新型喹啉-3-羧酸和嘧啶并喹啉衍生物作为潜在抗菌剂的合成

  摘要：

  描述了几种喹啉和嘧啶并喹啉衍生物的合成和体外抗菌评价。用磷酰氯或亚硫酰氯处理7-取代的喹啉-2(1H)-one-3-羧酸2a-c产生7-取代的2-氯喹啉-3-羧酸3a-c和7-取代的2 -Chloro-3-chlorocarbonylquinolines 5a-c 分别。化合物3a-c中的2-氯官能团被2-氨基噻唑或2-氨基吡啶取代得到2-(噻唑-2-基)氨基喹啉-3-羧酸4a-c或2-(吡啶-2-基)氨基喹啉-3-羧酸4d-f。在室温下用相同的杂环胺处理 5a-c 得到相应的 7-取代的 2-氯-3-杂基-氨基羰基喹啉 6a-f。四环9-取代的噻唑并[3', 2': 1, 2]嘧啶[4, 5-b] quinolin-5-ones 7a-c 和 10-取代的吡啶并 [1', 2': 1, 2] -pyrimido [4, 5-b] quinolin-6-ones 7d-f 通过加热 5a 合成-C

  DOI：

  10.1002/1521-4184(200212)335:9<403::aid-ardp403>3.0.co;2-9
• 作为产物：
  描述：

  2-氧代-1,2-二氢喹啉-3-羧酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 12.0h， 以74%的产率得到2-羟基-3-喹啉羧酸
  参考文献：
  名称：

  香豆素类抗真菌唑类化合物的抗真菌活性，作用方式变异性和亚细胞分布

  摘要：

  唑类抗真菌剂抑制麦角固醇的生物合成，麦角固醇是哺乳动物细胞中胆固醇的真菌等同物。在这里，我们报告了香豆素取代的吡咯类抗真菌药活性的调查。针对假丝酵母菌的筛选病原体，包括缺少CYP51的突变体（抗真菌唑的靶标）显示，该酶被三唑类抗真菌剂抑制，而咪唑类衍生物具有多种作用方式。与基于三唑的衍生物相比，带有咪唑的抗真菌剂能更有效地减少与真菌感染的持续和/或复发相关的拖尾生长。咪唑衍生物对哺乳动物细胞的毒性更大，并且更有效地抑制了CYP3A4的活性，而CYP3A4的活性是造成唑类毒性的主要原因之一。使用活细胞成像，我们发现，不管是位于内质网（是CYP51的细胞器）上的吡咯环荧光7-二乙基氨基香豆素基吡咯类化合物。

  DOI：

  10.1016/j.ejmech.2019.07.003

文献信息

• POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20180297994A1

  公开（公告）日：2018-10-18

  The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及肌动蛋白M2受体的阳性变构调节剂，特别是新型的7-取代的1-芳基萘啶-3-羧酰胺，以及其制备方法，单独或组合使用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。
• Carbostyril derivatives
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04578381A1

  公开（公告）日：1986-03-25

  Disclosed are carbostyril derivatives and their salts of the formulas ##STR1## The compounds have anti-peptic ulcer effects, and are useful as a treating agent for curing peptic ulcers in the digestive system, such as ulcers in the stomach and in the duodenum. The compounds particularly have prophylaxis and curing effects for treating chronic ulcers, for example experimental acetic acid-induced ulcers and cautery ulcers, with both low toxicity and few side-effects. Also disclosed are processes for preparing the compounds and for preparing pharmaceutical compositions containing them.

  揭示了化学式为##STR1##的羧基喹啉衍生物及其盐。这些化合物具有抗消化性溃疡作用，并可用作治疗消化系统中的消化性溃疡的治疗剂，例如胃和十二指肠溃疡。这些化合物特别具有预防和治疗慢性溃疡的效果，例如实验性乙酸诱导的溃疡和烧灼性溃疡，具有低毒性和少副作用。还揭示了制备这些化合物以及制备含有它们的药物组合物的方法。
• [EN] PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES<br/>[FR] DÉRIVÉS DE PHÉNOXYPYRIDINYLAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT D'ÉTATS PATHOLOGIQUES INDUITS PAR LA PHOSPHODIÉSTERASE 4 (PDE4)
  申请人：ASTRAZENECA AB

  公开号：WO2009144494A1

  公开（公告）日：2009-12-03

  The present invention provides a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.

  本发明提供了一种化合物的公式(I)，其中变量在此定义；以及制备这种化合物的方法；以及在治疗PDE4介导的疾病状态中使用这种化合物。
• 1,2-Dihydro-2-oxoquinoline derivatives
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US06329525B1

  公开（公告）日：2001-12-11

  A 1,2-dihydro-2-oxoquinoline derivative represented by the formula: wherein Ar is a pyridyl group or a group represented by the formula: (wherein X3 and X4 are the same or different, and are each a hydrogen atom, a halogen atom, a C1-5 alkyl group, a C1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group), Y is a nitrogen atom, CH or C(OH), R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom, or X1 and X2 taken together form an alkylenedioxy group, and n is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof.

  一种由以下公式表示的1,2-二氢-2-氧喹啉衍生物： 其中Ar是吡啶基或由以下公式表示的基团： （其中X3和X4相同或不同，分别为氢原子、卤素原子、C1-5烷基、C1-5烷氧基、羟基或三氟甲基基团），Y是氮原子、CH或C(OH)，R1和R2相同或不同，分别为氢原子、C1-10烷基、C3-15烷氧基烷基或C3-15烷基氨基烷基，或R1和R2与它们连接的氮原子一起形成环状氨基团，X1和X2相同或不同，分别为氢原子、C1-5烷基、C1-5烷氧基或卤素原子，或X1和X2一起形成烷二氧基基团，n为1到3的整数；或其药学上可接受的盐。
• Selective Inhibition of DNA Polymerase β by a Covalent Inhibitor
  作者：Shelby C. Yuhas、Daniel J. Laverty、Huijin Lee、Ananya Majumdar、Marc M. Greenberg

  DOI：10.1021/jacs.1c02453

  日期：2021.6.2

  has been closely linked to cancer. Selective inhibitors of this enzyme are lacking. Inspired by DNA lesions produced by antitumor agents that inactivate Pol β, we have undertaken the development of covalent small-molecule inhibitors of this enzyme. Using a two-stage process involving chemically synthesized libraries, we identified a potent irreversible inhibitor (14) of Pol β (KI = 1.8 ± 0.45 μM, kinact

  DNA 聚合酶 β (Pol β) 在 DNA 修复中起着至关重要的作用，并且与癌症密切相关。缺乏这种酶的选择性抑制剂。受使 Pol β 失活的抗肿瘤剂产生的 DNA 损伤的启发，我们着手开发这种酶的共价小分子抑制剂。使用涉及化学合成文库的两阶段过程，我们确定了Pol β的有效不可逆抑制剂 ( 14 ) ( K I = 1.8 ± 0.45 μM, k inact = (7.0 ± 1.0) × 10 –3 s –1 )。抑制剂14比其他 DNA 聚合酶选择性地灭活 Pol β。用14处理的 Pol β 胰蛋白酶消化物的 LC-MS/MS 分析鉴定了聚合酶结合位点内共价修饰的两个赖氨酸，其中一个先前被确定在DNA结合中起作用。荧光各向异性实验表明，用14预处理 Pol β可防止 DNA 结合。在野生型小鼠胚胎成纤维细胞 (MEF) 中使用前抑制剂 ( pro - 14 ) 的实验表明，抑制剂